Sarepta Therapeutics (NASDAQ:SRPT) Coverage Initiated by Analysts at Wolfe Research

Wolfe Research began coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research note released on Tuesday morning, Marketbeat Ratings reports. The brokerage issued a peer perform rating on the biotechnology company’s stock.

Several other brokerages have also weighed in on SRPT. Jefferies Financial Group lowered their target price on shares of Sarepta Therapeutics from $125.00 to $54.00 and set a “buy” rating on the stock in a research report on Monday. Piper Sandler lowered Sarepta Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $70.00 to $36.00 in a research note on Monday. Oppenheimer dropped their price objective on Sarepta Therapeutics from $184.00 to $123.00 and set an “outperform” rating for the company in a research note on Wednesday, May 7th. Scotiabank raised Sarepta Therapeutics from a “sector perform” rating to a “sector outperform” rating and set a $80.00 price objective for the company in a report on Friday, June 6th. Finally, BMO Capital Markets downgraded Sarepta Therapeutics from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $120.00 to $70.00 in a research report on Monday. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $74.13.

Sarepta Therapeutics Trading Up 3.0%

Shares of SRPT stock opened at $21.56 on Tuesday. The business’s fifty day moving average price is $45.00 and its 200 day moving average price is $84.80. The firm has a market capitalization of $2.12 billion, a PE ratio of -8.01 and a beta of 0.61. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.02 and a quick ratio of 2.46. Sarepta Therapeutics has a 1-year low of $18.30 and a 1-year high of $173.25.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) EPS for the quarter, missing the consensus estimate of $2.20 by ($5.62). The company had revenue of $744.86 million for the quarter, compared to analysts’ expectations of $685.75 million. Sarepta Therapeutics had a negative return on equity of 14.88% and a negative net margin of 11.12%. Sarepta Therapeutics’s revenue for the quarter was up 80.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.73 earnings per share. As a group, sell-side analysts forecast that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

Hedge Funds Weigh In On Sarepta Therapeutics

Institutional investors have recently modified their holdings of the company. Byrne Asset Management LLC acquired a new stake in Sarepta Therapeutics during the first quarter worth approximately $30,000. Center for Financial Planning Inc. acquired a new stake in shares of Sarepta Therapeutics during the first quarter worth $31,000. Ancora Advisors LLC grew its position in shares of Sarepta Therapeutics by 150.0% in the first quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 300 shares during the period. Steward Partners Investment Advisory LLC grew its position in shares of Sarepta Therapeutics by 164.4% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 312 shares of the biotechnology company’s stock valued at $38,000 after purchasing an additional 194 shares during the period. Finally, Banque Transatlantique SA acquired a new position in Sarepta Therapeutics in the first quarter valued at $44,000. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.